Curious to see your top suppliers emissions?
Book a demo for a pilot project
college ter beoordeling van geneesmiddelen
Medicinal and Botanical ManufacturingNetherlands
Last verified 4 months agocbg-meb.nl
The College ter Beoordeling van Geneesmiddelen (CBG), headquartered in the Netherlands, plays a pivotal role in the pharmaceutical industry by overseeing the evaluation and approval of medicinal products. Established in 2001, the CBG has become a cornerstone of drug regulation, ensuring that medicines meet stringent safety, efficacy, and quality standards.
Operating primarily within the Netherlands, the CBG collaborates with various European regulatory bodies, enhancing its influence across the EU. Its core services include the assessment of new drugs, monitoring of existing medications, and providing guidance on pharmaceutical regulations. The CBG's commitment to public health and safety has solidified its position as a trusted authority in the field, making significant contributions to the advancement of healthcare in the region.
16
DitchCarbon score
-8 vs industry average
college ter beoordeling van geneesmiddelen’s score of 16 is lower than 14% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at college ter beoordeling van geneesmiddelen?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very High
Medicinal and Botanical Manufacturing is among the most carbon-intensive industries
Industry performance
0.420
20182025
The Medicinal and Botanical Manufacturing industry has reduced its overall emissions by 28% since 2018
Reported emissions
No reported emissions data is available for college ter beoordeling van geneesmiddelen yet.
college ter beoordeling van geneesmiddelen's reported carbon emissions
As of the latest reporting, college ter beoordeling van geneesmiddelen has not disclosed any carbon emissions data, indicating a lack of available figures for their Scope 1, Scope 2, and Scope 3 emissions. Consequently, there are no specific reduction targets or climate commitments outlined in their initiatives. The absence of emissions data suggests that the organisation may still be in the early stages of developing a comprehensive climate strategy or reporting framework. Without concrete figures or commitments, it is challenging to assess their environmental impact or progress towards sustainability goals.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
college ter beoordeling van geneesmiddelen’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for college ter beoordeling van geneesmiddelen yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for college ter beoordeling van geneesmiddelen yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more